405 results on '"Holdenrieder, Stefan"'
Search Results
2. German Society for Clinical Chemistry and Laboratory Medicine – areas of expertise: Division reports from the German Congress of Laboratory Medicine 2022 in Mannheim, 13–14 October 2022
3. Moving Forward on Tumor Pathology Research Reporting: A Guide for Pathologists From the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group
4. Quantification of ventricular stress in univentricular hearts during early childhood using age-independent zlog-NT-proBNP
5. Systemic inflammatory response syndrome in patients undergoing transcatheter aortic valve implantation
6. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers
7. CA125: a novel cardiac biomarker for infants with congenital diaphragmatic hernia
8. A New Hierarchy of Research Evidence for Tumor Pathology: A Delphi Study to Define Levels of Evidence in Tumor Pathology
9. PATHFINDER-CHD: prospective registry on adults with congenital heart disease, abnormal ventricular function, and/or heart failure as a foundation for establishing rehabilitative, prehabilitative, preventive, and health-promoting measures: rationale, aims, design and methods
10. The Percentage of [-2]Pro-Prostate-Specific Antigen and the Prostate Health Index Outperform Prostate-Specific Antigen and the Percentage of Free Prostate-Specific Antigen in the Detection of Clinically Significant Prostate Cancer and Can Be Used as Reflex Tests
11. Profiling disease and tissue-specific epigenetic signatures in cell-free DNA
12. The rising tide of cell-free DNA profiling: from snapshot to temporal genome analysis
13. Pan-cancer screening by circulating tumor DNA (ctDNA) – recent breakthroughs and chronic pitfalls
14. Liquid profiling – circulating nucleic acid diagnostics gains momentum
15. Requirements for electronic laboratory reports according to the German guideline Rili-BAEK and ISO 15189
16. Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes
17. Predicting Major Adverse Cardiovascular Events in Children With Age-Adjusted NT-proBNP
18. The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?
19. Assessment of SARS-CoV-2 rapid antigen tests
20. Satellite 2 repeat DNA in blood plasma as a candidate biomarker for the detection of cancer
21. Increased proBNP during extracorporeal life support (ECLS) is associated with poor outcome in neonates with congenital diaphragmatic hernia
22. Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention.
23. Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study.
24. Targeted Sequencing of Human Satellite 2 Repeat Sequences in Plasma cfDNA Reveals Potential Breast Cancer Biomarkers.
25. Influence of a 7‐day Transalpine Trail Run on cardiac biomarkers and myocardial function.
26. Bioactive adrenomedullin (bio-ADM) is associated with endothelial dysfunction in infants and children with complex congenital heart disease undergoing open-heart surgery on cardiopulmonary bypass.
27. Aggrecan: a new biomarker for acute type A aortic dissection
28. Serial profiling of cell-free DNA and nucleosome histone modifications in cell cultures
29. SARS-CoV-2 antibody testing—questions to be asked
30. Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation
31. Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease
32. Biological variability of cell-free DNA in healthy females at rest within a short time course
33. Value of Rotational Thromboelastometry and Impedance Aggregometry for Evaluating Coagulation Disorders in Patients With Cyanotic and Nongenetic Congenital Heart Disease
34. The emerging role of cell-free DNA as a molecular marker for cancer management
35. Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19.
36. Lung cancer biomarkers: Raising the clinical value of the classical and the new ones.
37. Lung cancer tumor marker analysis: A clinical laboratory perspective.
38. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
39. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
40. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
41. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update.
42. A pocket companion to cell-free DNA (cfDNA) preanalytics.
43. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – A CEPAC-TDM biomarker substudy.
44. Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer.
45. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
46. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
47. Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies.
48. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
49. Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies.
50. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.